# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Myriad's Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiat...
Piper Sandler analyst John Peterson maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and raises the price target from ...
Leerink Partners analyst Puneet Souda upgrades Myriad Genetics (NASDAQ:MYGN) from Market Perform to Outperform and raises th...
Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.1...